Agios Pharmaceuticals AGIO Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

IncyteINCY

——

BioCryst PharmaceuticalsBCRX

——

BridgeBio PharmaBBIO

——

Ligand PharmaceuticalsLGND

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's convertible preferred stock outstanding shares?: Agios Pharmaceuticals (AGIO) reported convertible preferred stock outstanding shares of 0 in Q1 2026.